Company Information

  

Address: 175 PORTLAND STREET
4TH FLOOR 
City: BOSTON 
State: MA 
Zip Code: 02114 
Telephone: 617-622-4003 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by both rare and prevalent metabolic diseases including type 2 diabetes, Prader-Willi syndrome, or PWS, and potentially other metabolically related disorders. We have pioneered the study of methionine aminopeptidase 2, or MetAP2, inhibitors and are focused on developing novel therapeutics that treat biological mechanisms that underlie metabolic disorders through the MetAP2 pathway. Our lead product candidate is ZGN-1061, a novel fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is currently being profiled for its utility in the treatment of type 2 diabetes. Type 2 diabetes is a prevalent, chronic, progressive, multifactorial disorder that leads to increased microvascular and macrovascular disease, and as such increases risk of death from cardiovascular disease, stroke, and kidney failure.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2018-2.09NAN/E
03/2018-2.00NAN/E
12/2017-1.90NAN/E
09/2017-1.80NAN/E
06/2017-1.88NAN/E
03/2017-1.95NAN/E
12/2016-2.12NAN/E
09/2016-2.60NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.14Total Liab/Total Assets0.26
Net Inc/Total Assets-0.49Total Liab/Inv Cap0.28
Net Inc/Inv Cap-0.53Total Liab/Comm Equity0.07
Pretax Inc/Net SalesNAInterest Coverage Ratio-314.32
Net Inc/Net SalesNACurr Debt/EquityNA
Cash Flow/Net SalesNALTD/Equity0.26
SG&A/NetSalesNATotal Debt/Equity0.26
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio14.39
Inventory TurnoverNACurrent Ratio14.39
Inventory Day SalesNANet Rec/Curr Assets0.01
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  6/30/2018 3/31/2018 12/31/2017 9/30/2017
Total Revenues(Net Sales) 0.00 0.00 0.00 0.00
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 3.35 3.27 2.45 3.12
Operating Income -15.56 -15.70 -13.36 -12.84
Interest Exp 0.47 0.46 0.01 0.03
Pretax Income -15.78 -15.96 -13.09 -12.59
Other Income 0.25 0.20 0.28 0.29
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -15.78 -15.96 -13.09 -12.59

Balance Sheet (Millions)

Assets 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Cash & Short Term Investments 75.85 89.07 102.05 93.18
Receivables - Total 0.90 0.93 0.95 0.47
Inventories - Total NA NA NA NA
Total Current Assets 78.03 91.42 104.93 95.66
Net Property, Plant & Equipment 0.47 0.48 0.53 0.55
Total Assets 79.80 92.61 105.51 96.26
Liabilities        
Accounts Payable 7.46 7.46 7.29 5.77
Debt in Current Liabilities 1.82 NA 0.00 1.27
Total Current Liabilities 9.28 7.46 7.29 7.03
Long-Term Debt 18.50 20.16 20.00 NA
Total Liabilities 27.78 27.62 27.29 7.03
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.03 0.03 0.03 0.03
Retained Earnings -321.31 -305.53 -289.58 -276.49
Treasury Stock NA NA NA NA
Total Stockholders' Equity 52.02 65.00 78.22 89.23
Total Liabilities and Stockholders' Equity 79.80 92.61 105.51 96.26

Cash Flow Summary (Millions)

Categories 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Net Cash Provided by Operating Activities -13.31 -13.27 -9.84 -12.09
Net Cash Provided by Investing Activities 8.34 17.96 12.69 0.28
Net Cash Provided by Financing Activities -0.02 0.26 18.73 -0.72

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.00-14.03--
12/20140.00-36.48-0.30
12/20150.00-74.29-2.78
12/20160.00-57.88-2.12
12/20170.00-52.03-1.90
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/1810025,73069.91




Report Date : 9/17/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.